JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 178 filers reported holding JUNO THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is 1.38 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $125,087,000 | +59.4% | 2,736,527 | +56.5% | 0.02% | +66.7% |
| Q3 2017 | $78,462,000 | +46.9% | 1,749,038 | -2.1% | 0.01% | +28.6% |
| Q2 2017 | $53,412,000 | +25.5% | 1,786,938 | -6.9% | 0.01% | +40.0% |
| Q1 2017 | $42,574,000 | +17.7% | 1,918,592 | 0.0% | 0.01% | 0.0% |
| Q4 2016 | $36,165,000 | -62.2% | 1,918,592 | -39.8% | 0.01% | -61.5% |
| Q3 2016 | $95,635,000 | -56.4% | 3,186,758 | -44.2% | 0.01% | -56.7% |
| Q2 2016 | $219,386,000 | +0.9% | 5,707,235 | 0.0% | 0.03% | 0.0% |
| Q1 2016 | $217,388,000 | -32.2% | 5,707,235 | -21.7% | 0.03% | -30.2% |
| Q4 2015 | $320,683,000 | +10.7% | 7,293,224 | +2.5% | 0.04% | +4.9% |
| Q3 2015 | $289,608,000 | -17.4% | 7,117,424 | +8.2% | 0.04% | -8.9% |
| Q2 2015 | $350,714,000 | -10.1% | 6,576,290 | +2.3% | 0.04% | -10.0% |
| Q1 2015 | $389,961,000 | +42.6% | 6,428,631 | +22.8% | 0.05% | +38.9% |
| Q4 2014 | $273,396,000 | – | 5,235,467 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |